健康元：健康元药业集团股份有限公司2021年年度报告（英文版）.PDF

1、 1 Important Notice I The Board of Directors(the“Board”),the Board of Supervisors and directors,supervisors and senior management of the Company hereby warrant the truthfulness,accuracy and completeness of the contents of this annual report(the“Report”),and that there are no false representations,mi

2、sleading statements or material omissions contained in the Report,and severally and jointly accept responsibility.II All directors of the company have attended the Board meeting.III Grant Thornton(Special General Partnership)Issued a standard unqualified audit report for the Company.IV Mr.Zhu Baoguo

3、(朱 保 国),the person-in-charge of the Company,and Mr.Qiu Qingfeng(邱 庆 丰),the person-in-charge of accounting work and the person-in-charge of the accounting department(the head of the accounting department)declare that they hereby warrant the truthfulness,accuracy and completeness of the financial stat

4、ements contained in the Report.V Profit distribution plan or plan for conversion of capital reserve to share capital approved by the Board resolution during the Reporting Period Based on the audit conducted by Grant Thornton(Special General Partnership),the Parent Company generated net profit of RMB

5、 1,248,797,138.93,10%of which was contributed to the statutory surplus reserve,namely RMB 124,879,713.89,the remainder of which,together with undistributed profits from last year RMB 564,932,141.19,subtracting cash dividends from last year RMB 288,675,388.05,is the current year Profits available for

6、 distribution to shareholders RMB 1,400,174,178.18.The Company plans to distribute cash dividends for the fiscal year 2021,based on the total number of shares for dividend distribution,which is defined by the total shares of Company,minus the shares in the Share Repurchase Account,on the equity regi